TNF Pharmaceuticals is developing MYMD-1®, a synthetic plant alkaloid that targets immunometabolic dysregulation to treat autoimmune diseases and age-related conditions. Additionally, the company is advancing Supera-CBD, a synthetic cannabidiol with enhanced bioavailability and potency, aimed at providing a safer alternative to traditional botanical CBD products for chronic pain and anxiety management.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for autoimmune diseases and age-related conditions often target symptoms rather than the underlying causes, and can have significant side effects. There is a need for therapies that address the root of immunometabolic dysregulation with improved safety profiles. Additionally, botanical CBD products can contain impurities and lack consistent bioavailability.
Solution
TNF Pharmaceuticals is developing two synthetic therapeutics: MYMD-1 and Supera-CBD. MYMD-1 is a synthetic plant alkaloid in clinical stage development that targets immunometabolic dysregulation to treat autoimmune diseases, aging-related conditions, and immune-mediated depression. MYMD-1 inhibits pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-17A, and can cross the blood-brain barrier, offering potential for treating neuroinflammation. Supera-CBD is a synthetic cannabidiol derivative designed to target CB2 receptors with enhanced bioavailability and potency compared to botanical CBD, providing a potentially safer and more effective alternative for managing chronic pain, anxiety, and sleep disorders.
Target Audience
The primary target audience includes individuals suffering from autoimmune diseases, age-related conditions such as sarcopenia and frailty, chronic pain, anxiety, sleep disorders, and immune-mediated depression, as well as physicians seeking safer and more effective treatment options.
Features
- MYMD-1: Orally available cytokine inhibitor targeting TNF-α, IL-6, and IL-17A
- MYMD-1: Demonstrated ability to cross the blood-brain barrier
- MYMD-1: Shown to ameliorate the severity and incidence of thyroiditis in preclinical studies
- MYMD-1: Demonstrated potential for reducing the activity of molecules driving inflammation and scarring in idiopathic pulmonary fibrosis (IPF)
- Supera-CBD: Synthetic cannabidiol with enhanced bioavailability and potency
- Supera-CBD: Targets CB2 receptors effectively